WuXi AppTec Forms China Cancer Immunotherapy JV with Juno Therapeutics

WuXi AppTec. China's largest CRO/CMO, and Juno Therapeutics of Seattle have formed a 50-50 joint venture to bring Juno's promising immuno-oncology drugs to China. The new company, JW Biotechnology, will be based in Shanghai and will eventually own China rights to Juno's products, once certain unspecified conditions are met. Juno will be paid an upfront payment in equity (presumably JV equity), plus milestone payments and royalties on sales. WuXi will use its CRO capabilities to pursue China approval of the products. Through its venture arm, WuXi has already invested in Juno. More details.... Stock Symbol: (NSDQ: JUNO) Share this with colleagues: // //